Life's Grossman starts VC adventure; CEO takes stock
This article was originally published in Clinica
Following the completion of its $13.6bn takeover by Thermo Fisher Scientific, former Life Technologies executive Paul Grossman has joined venture capital firm Telegraph Hill Partners as a venture partner. Dr Grossman was head of global strategy and corporate development at Life, where he was responsible for the company’s corporate strategy, licensing, business development and acquisition activities. Meanwhile, former Life chairman and CEO Greg Lucier is taking some time out after running a public company for 11 years, he told Clinica’s sister publication Scrip. Mr Lucier was appointed CEO of Invitrogen in 2003, which merged with Applied Biosystems in 2008 to form Life. He will remain active as a board member at companies including NuVasive, RainTree Oncology Services, Carefusion and the Sanford-Burnham Medical Institute in San Diego. "In time, I will get back into being a CEO," he said.
You may also be interested in...
Thermo Fisher expects the deal to improve its portfolio of specialty diagnostics for clinical labs while its genetic analysis technologies, biosciences reagents and consumable products will complement Qiagens’ sample preparation and assay technologies.
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.